10-Q: TG Therapeutics Secures $750M Loan, Boosts Buyback

TG Therapeutics refinanced its debt with a new $750 million credit facility, adding $500 million in non-dilutive capital, and increased its share repurchase program to $300 million, while reporting strong Q1 2026 revenue growth.

Summary

• Refinanced a $250 million Initial Term Loan with a new $750 million senior secured credit facility from Blue Owl Capital, resulting in a net raise of $500 million in non-dilutive capital.
• Increased the share repurchase program from $100 million to $300 million.
• Repurchased $100 million of common stock during Q1 2026 under the 2025 Share Repurchase Program.
• Reported total revenue of $204.9 million for Q1 2026, a significant increase from $120.9 million in Q1 2025.
• Net product revenue from U.S. sales of BRIUMVI was $194.8 million in Q1 2026, compared to $119.7 million in Q1 2025.
• Sales of BRIUMVI to ex-U.S. licensing partner Neuraxpharm were $6.5 million in Q1 2026.
• Achieved net income of $19.8 million ($0.14 basic EPS, $0.12 diluted EPS) for Q1 2026, up from $5.1 million ($0.03 basic and diluted EPS) for Q1 2025.
• Cash, cash equivalents, and investment securities (excluding equity investments) totaled $572.8 million as of March 31, 2026.
• The Phase 3 trial for subcutaneous BRIUMVI completed enrollment, with topline data expected around year-end 2026 or Q1 2027.
• Five-year data from the open-label extension of Phase 3 ULTIMATE I and II studies for BRIUMVI were published in JAMA Neurology in February 2026.
• FDA clearance of IND for azer-cel for progressive forms of MS was received in August 2024, and the first patient was dosed in a Phase 1 trial in August 2025.
• Incurred a $9.2 million loss on extinguishment of debt in Q1 2026 due to the refinancing transaction.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, highlighted by significant revenue growth, a return to profitability, and a substantial non-dilutive capital raise that enhances liquidity and supports strategic initiatives like the increased share repurchase program. The progress in clinical trials for subcutaneous BRIUMVI and azer-cel further strengthens the long-term outlook.

Positives

• Total revenue increased significantly to $204.9 million in Q1 2026 from $120.9 million in Q1 2025, driven by BRIUMVI sales.
• U.S. net product revenue for BRIUMVI reached $194.8 million in Q1 2026, indicating increased market penetration.
• Achieved net income of $19.8 million in Q1 2026, a substantial improvement from $5.1 million in Q1 2025.
• Successfully refinanced debt with a new $750 million senior secured credit facility, providing $500 million in net new non-dilutive capital.
• The share repurchase program was increased to $300 million, demonstrating confidence in financial position and commitment to shareholder returns.
• Completed enrollment for the Phase 3 trial of subcutaneous BRIUMVI, with topline data anticipated by year-end 2026 or Q1 2027.
• Positive five-year data from the open-label extension of ULTIMATE I and II studies for BRIUMVI were published in JAMA Neurology.
• FDA clearance of IND for azer-cel for progressive MS and the first patient dosed in a Phase 1 trial advance the pipeline.
• Maintained a strong liquidity position with $572.8 million in cash, cash equivalents, and investment securities as of March 31, 2026, projected to fund operations for more than twelve months.
• The company was in compliance with all financial covenants as of March 31, 2026.

Negatives

• Incurred a $9.2 million loss on extinguishment of debt due to the refinancing of the Initial Term Loan.
• The accumulated deficit remains substantial at approximately $1.1 billion as of March 31, 2026, reflecting historical operating losses.
• Operating cash flow was still negative at $(17.9) million for Q1 2026, despite year-over-year improvement.
• Other income decreased to $2.4 million in Q1 2026 from $3.6 million in Q1 2025, mainly due to less income earned from investments.
• Selling, general and administrative expenses increased to $88.2 million in Q1 2026 from $50.3 million in Q1 2025, primarily due to marketing and personnel costs for BRIUMVI commercialization.
• Interest expense increased to $7.7 million in Q1 2026 from $6.8 million in Q1 2025 due to the new financing agreement.

Risks

• If marketing approval for BRIUMVI or future product candidates is not broadly accepted by physicians, patients, healthcare payors, and the medical community, revenues from product sales will be limited.
• Regulatory approvals may be subject to limitations on indicated uses or requirements for costly post-marketing studies, or marketing approval may be unable to be maintained.
• Approved products may cause undesirable side effects or adverse events after approval, leading to significant negative consequences such as regulatory withdrawal or product liability.
• Estimates for target patient populations of BRIUMVI and other product candidates may be inaccurate, or approvals may be based on narrower patient definitions, adversely affecting revenue and profitability.
• Substantial competition from other pharmaceutical and biotechnology companies, many with greater resources, may reduce or eliminate commercial opportunities.
• Products may become subject to unfavorable pricing regulations or third-party payor coverage and reimbursement policies, harming the business.
• Product liability lawsuits could result in substantial liabilities and limit commercialization efforts.
• The company has incurred substantial operating losses since inception and may incur future losses, with no assurance of sustained profitability.
• While not currently expected, additional capital may be needed, and inability to raise it could delay, limit, reduce, or eliminate drug development or commercialization efforts.
• The level of indebtedness and debt service obligations could adversely affect financial condition and make funding operations more difficult.
• Inability to maintain or obtain regulatory approval for products or product candidates, or significant delays, would materially harm the business.
• Results of preclinical studies and early clinical trials are not necessarily predictive of future results; later trials may not be favorable, or interim/preliminary data may change.
• Biologics carry unique risks and uncertainties in development, manufacturing, and sale.
• Product candidates are subject to extensive, costly, and time-consuming regulation, which can cause unanticipated delays or prevent required approvals.
• New legislation, regulatory proposals, and third-party payor initiatives may increase compliance costs and adversely affect marketability, collaborations, and capital raising.
• Inadequate funding, government shutdowns, workforce reductions, or other policy changes affecting regulatory agencies could hinder their ability to perform normal business functions.
• Failure to adequately understand and comply with local laws and customs in new international markets may lead to losses or adversely affect business.
• Reliance on third parties to generate clinical, preclinical, and other data; non-performance could delay or prevent regulatory approval or commercialization.
• Reliance on third parties for manufacturing and testing increases the risk of insufficient quantities, unacceptable cost/quality, or supply disruptions, especially with single-source suppliers.
• Disputes with or non-performance by licensors (e.g., LFB Biotechnologies, Precision BioSciences) could adversely affect the ability to develop and commercialize products.
• Dependence on collaboration and commercialization partners (e.g., Neuraxpharm); unsuccessful relationships or terminations could negatively impact business and net product revenue.
• Inability to obtain and protect intellectual property and proprietary technologies, or challenges to patent validity and enforceability, may impair commercialization.
• Failure to obtain patent term extensions (e.g., under the Hatch-Waxman Act) could materially harm the business by shortening exclusivity periods.
• Lawsuits for infringing third-party intellectual property rights would be costly and time-consuming, with potentially unfavorable outcomes.
• Need to license certain intellectual property from third parties, which may not be available or on commercially reasonable terms.
• Inability to protect the confidentiality of trade secrets could harm business and competitive position.
• Failure to attract and keep key management, commercial, and clinical development personnel may hinder successful development or commercialization.
• Difficulties in managing business development and expansion (e.g., acquisitions, strategic alliances) could disrupt operations.
• Certain executive officers, directors, principal stockholders, and their affiliates maintain the ability to exercise significant influence over the company.
• Internal information technology systems, or those of third-party CROs, CMOs, or other contractors, are vulnerable to failures or security breaches.
• Unfavorable global economic conditions and changes in government regulations (e.g., tariffs, BIOSECURE Act) could adversely affect business, financial condition, or results of operations.
• Stock price is, and is expected to remain, volatile, limiting investors' ability to sell stock at a profit.
• Risks related to corporate social responsibility and reputational matters could negatively impact business and financial results.
• Climate change or legal/regulatory measures to address it may negatively affect business, supply chain, and financial condition.
• Ability to utilize net operating loss (NOL) carryforwards and certain other tax attributes may be limited by ownership changes under Section 382 of the Internal Revenue Code.
• Certain anti-takeover provisions in governing documents and Delaware law could make a third-party acquisition difficult, potentially limiting stock price.
• Contracts with government entities may involve future funding and compliance risks, including potential termination or reduction.
• Relationships with customers and third-party payors are subject to fraud and abuse laws, false claims laws, transparency, and other healthcare regulations, exposing the company to penalties.
• Shortages in animal availability or possible restrictions on animal testing could affect research and development activities.

Future Outlook

The company anticipates that its existing cash, cash equivalents, and investment securities, along with projected future revenues, will be sufficient to fund operations and meet liquidity needs for more than twelve months after the filing date. Expenses are expected to increase due to continued growth, expansion of clinical programs, and potential commercialization of additional product candidates, with significant research and development expenses anticipated for the foreseeable future. Topline data for the Phase 3 trial evaluating subcutaneous BRIUMVI is expected around year-end 2026 or Q1 2027. The company may seek significant additional financing in the future to support strategic initiatives and ongoing/planned operations, with future capital requirements dependent on factors like BRIUMVI commercialization scope, timing of receivables collection, clinical trial timing/design, and costs of licensing/acquiring new product candidates. Cost of revenue and gross margin are expected to normalize as pre-approval inventory is depleted.

Management Comments

• "Based on our current operating plan and results, we anticipate that our existing cash, cash equivalents, and investment securities, together with projected future revenues, will be sufficient to fund operations and meet our liquidity needs for more than twelve months after the date of filing of this Quarterly Report on Form 10-Q."
• "We expect our expenses to increase as we continue to grow and expand our clinical programs and pursue the potential commercialization of additional product candidates."
• "We anticipate incurring significant research and development expenses related to these activities for the foreseeable future."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry is highly competitive, with significant R&D and commercialization costs. The focus on B-cell mediated diseases, particularly Multiple Sclerosis, places TG Therapeutics in a market with established players and ongoing innovation. The successful refinancing and increased share buyback program indicate a strong financial position relative to some smaller biotechs, allowing for continued investment in pipeline and commercial expansion. The emphasis on a subcutaneous formulation of BRIUMVI aligns with broader industry trends towards more convenient administration methods for chronic conditions.

Comparison to Industry Standards

• The company's strategy of developing a subcutaneous formulation of ublituximab is a common industry practice to enhance patient convenience and market differentiation, similar to how other biologics have evolved (e.g., Humira, Ocrevus).
• The pursuit of CAR T cell therapy (azer-cel) for autoimmune diseases positions the company in an emerging and highly innovative area, comparable to efforts by larger pharmaceutical companies like Bristol Myers Squibb (BMS) and Johnson & Johnson (J&J) who are also exploring CAR T beyond oncology.
• The tiered double-digit royalties on net product sales up to 30% from the Neuraxpharm commercialization agreement are within the typical range for ex-U.S. licensing deals for specialty pharmaceuticals.
• The $750 million senior secured credit facility with an option for an additional $250 million, totaling up to $1 billion, is a substantial non-dilutive financing arrangement, reflecting confidence from lenders like Blue Owl Capital in the company's commercial prospects, particularly for a company of its stage.

Corporate Governance

Legal Proceedings

• The company and its subsidiaries are not a party to, and its property is not the subject of, any material pending legal proceedings.
• The company faces a risk of product liability exposure related to the testing of product candidates in human clinical trials and commercialization of BRIUMVI.
• The company may be involved in lawsuits to protect or enforce its patents or the patents of its licensors, which could be expensive, time-consuming, and unsuccessful.
• The company or its partners may be sued for infringing intellectual property rights of third parties, which would be costly and time-consuming, with potentially unfavorable outcomes.
• The company is exposed to liability risks under the Foreign Corrupt Practices Act (FCPA) or similar anti-bribery laws in international interactions.
• The company is subject to fraud and abuse laws, false claims laws, transparency and disclosure laws, health information and security laws, and other healthcare laws and regulations, which could expose it to criminal sanctions, civil penalties, and exclusion from government healthcare programs.

Related Party Transactions

• The Office Agreement with Fortress Biotech, Inc. (FBIO) to occupy office space in New York City is treated as a related party transaction. In February 2026, FBIO entered into a sublease agreement, and the Office Agreement was amended to reduce the company's share of rent and other costs for the remaining lease term.

Stakeholder Impact

• Shareholders: Benefit from increased share repurchase program, potential for reduced dilution from non-dilutive capital raise, and improved financial performance (net income, revenue growth). Risk of stock price volatility.
• Employees: Continued investment in commercial organization and clinical programs suggests stable to growing employment opportunities.
• Customers (Healthcare Providers/Patients): Potential for new product formulations (subcutaneous BRIUMVI) offering increased convenience and flexibility. Continued availability of BRIUMVI.
• Creditors (Blue Owl Capital): New $750 million senior secured credit facility indicates continued confidence and a strong lending relationship.
• Licensing Partners (Neuraxpharm, Precision BioSciences, MaxCyte): Continued collaboration and potential for milestone/royalty payments based on product success.

Next Steps

• Continue commercialization activities for BRIUMVI, focusing on expanding prescriber awareness, increasing penetration across infusion centers and neurology practices, securing payer coverage, and supporting patient access.
• Anticipate topline data from the Phase 3 trial evaluating subcutaneous BRIUMVI around year-end 2026 or Q1 2027.
• Continue advancing early-stage development activities for azer-cel in autoimmune diseases.
• Actively evaluate complementary products, technologies, and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
• Continue to invest in the commercial organization, infrastructure, and internal capabilities to support lifecycle management and potential expansion of BRIUMVI's clinical and commercial profile.
• Monitor and manage expenses as clinical programs expand and potential commercialization of additional product candidates is pursued.
• Potentially seek additional financing in the future to support strategic initiatives and ongoing/planned operations.
• Make scheduled quarterly amortization payments for the 2026 Term Loan commencing with the fiscal quarter ending March 31, 2030.

Key Dates

Recommendation

The company demonstrated robust financial performance with significant revenue growth and a return to profitability in Q1 2026. The successful refinancing of debt, securing $500 million in net new non-dilutive capital, substantially strengthens the balance sheet and provides ample liquidity for future operations. The increased share repurchase program signals strong management confidence and a commitment to shareholder value. Positive clinical updates for subcutaneous BRIUMVI and the advancement of azer-cel further de-risk the pipeline and offer future growth catalysts. While risks inherent to the biopharmaceutical industry remain, the current financial and operational trajectory suggests a compelling investment opportunity.

Keywords

Biotechnology, Pharmaceuticals, Multiple Sclerosis, BRIUMVI, Ublituximab, Azer-cel, CAR T therapy, Autoimmune diseases, SEC filing, 10-Q, Financial results, Debt refinancing, Share repurchase, Clinical trials, Regulatory approval, Commercialization, Drug development, Blue Owl Capital, Neuraxpharm, Precision BioSciences, MaxCyte